Once-daily intramuscular amikacin for outpatient treatment of lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli in children

Figures & data

Table 1 Treatment outcomes and adverse events of outpatient amikacin therapy (n=53)

Outcome	n (%)
Clinical and microbiological outcomes
Favorable clinical and bacteriological responses	51 (96)
Poor clinical and bacteriological responses	1 (2)
Relapse	1 (2)
Adverse events
Nephrotoxicity	0 (0)
Ototoxicity	0 (0)

Figure 1 The antimicrobial resistance profiles of extended-spectrum β-lactamase-producing Escherichia coli isolates (n=53).

Note: *Carbapenems: meropenem, imipenem and ertapenem included.